GHRP-6 dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL (2500 mcg/mL). A 100 mcg dose equals 4 units on a U100 insulin syringe.

   Open tool →
2. 2

   Measure the dose

   Typical GHRP-6 dose is 0.1 mg (100 to 200 mcg per injection, 2 to 3 times daily. Above 200 mcg shows diminishing GH return but escalating hunger.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer 2-3x daily. Half-life of 0.5 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No controlled human cycling data.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: intense hunger; water retention; vivid dreams; head pressure or flushing. Stop or reduce dose if tolerability breaks down.

Why this dose

Hexapeptide agonist of GHS-R1a (ghrelin receptor). Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs, with strong central NPY/AgRP appetite signaling and modest cortisol and prolactin release.

The typical dose (0.1 mg) reflects 100 to 200 mcg per injection, 2 to 3 times daily. Above 200 mcg shows diminishing GH return but escalating hunger.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

GHRP-6 is administered via the subcutaneous or intravenous routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Onset of action runs around 15 minutes after administration. Peak effect lands near 30 minutes post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Short ~15 to 60 minute plasma half-life produces a brief GH pulse returning to baseline within 2 to 3 hours.

Cycling and tolerance

Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No controlled human cycling data.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• First-generation hexapeptide ghrelin-receptor agonist; foundational to the GHRP class
• Strongest appetite stimulation of any synthetic GHRP at equivalent GH doses
• Produces measurable cortisol and prolactin rise alongside the GH pulse
• Anecdotal protocols use 100 to 200 mcg subcutaneously 2 to 3 times daily on an empty stomach
• Largely superseded by ipamorelin (cleaner profile) and GHRP-2 (stronger pulse) for body-composition use
• Banned by WADA under S2; detection methods validated in accredited labs

Side effects and interactions

Common side effects

• intense hunger
• water retention
• vivid dreams
• head pressure or flushing
• tingling at injection site

Notable interactions

• insulin (moderate): sustained GH can blunt insulin sensitivity over weeks
• corticosteroids (moderate): blunt GH response and amplify cortisol load
• CJC-1295 (minor): synergistic GH release; commonly co-administered
• sermorelin (minor): additive GH release via parallel GHRH and ghrelin pathways

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full GHRP-6 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Not scheduled (research chemical)

Pregnancy

Insufficient data; not recommended

Legal status

Not FDA approved; research-use-only grey market; banned by WADA

Do not use if

• pregnancy
• active malignancy
• history of pituitary tumor
• uncontrolled diabetes
• prolactin sensitivity

Related research